OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Tendulkar Discusses Post-Prostatectomy Radiation Therapy

January 17th 2017

Rahul Tendulkar, MD, associate staff, Radiation Oncology, Cleveland Clinic, discusses post-prostatectomy radiation therapy and its impact on reducing prostate cancer mortality.

Dr. Rassiwala on Results of "All-comers" Downstaging Protocol

January 17th 2017

Jasmine Rassiwala, MD, resident physician, University of California, San Francisco, discusses the analysis of the “all-comers” downstaging protocol, which investigated whether there were upper limits in tumor burden for successful downstaging of patients with hepatocellular carcinoma to liver transplant.

Dr. Bruix on Regorafenib in Second-Line HCC

January 17th 2017

Jordi Bruix, MD, head of the Barcelona Clinic Liver Cancer at University of Barcelona, discusses positive results with the use of regorafenib as a second-line treatment in patients previously treated with sorafenib in advanced hepatocellular carcinoma.

Dr. Thompson on Challenges Facing the Field of Multiple Myeloma

January 17th 2017

Michael A. Thompson, MD, PhD, medical director, precision medicine, Vince Lombardi Cancer Clinic, Aurora Health Care, discusses some of the challenges facing the field of multiple myeloma.

Dr. Burgess on Pembrolizumab in Sarcoma

January 17th 2017

In the phase II SARC028 trial, single-agent pembrolizumab (Keytruda) demonstrated antitumor activity in patients with advanced soft tissue and bone sarcomas.

Dr. McDermott on VEGF Plus PD-1 in Renal Cell Carcinoma

January 14th 2017

David F. McDermott, MD, Director of Biologic Therapy and Cutaneous Oncology Programs, Hematology and Oncology at the Beth Israel Deaconess Medical Center, discusses the combination of VEGF plus PD-1 in renal cell carcinoma (RCC).

Dr. Sherman on the Role of Regorafenib in Liver Cancer

January 14th 2017

Morris Sherman, MD, PhD, professor of Medicine at University of Toronto, discusses the emergence of regorafenib (Stivarga) and how it fits into the treatment of hepatocellular carcinoma (HCC).

Dr. Markman on Immune Targeting in Ovarian Cancer

January 14th 2017

Maurie Markman, MD, president of Medicine and Science, Cancer Treatment Centers of America, editor-in-chief, OncologyLive, discusses the development of immune targeting in ovarian cancer.

Dr. von Tresckow on "Sequential Triple-T" Trial in CLL

January 14th 2017

Julia von Tresckow, MD, specialist in oncology, University of Cologne, Department of Internal Medicine, and Center of Integrated Oncology Cologne-Bonn, German CLL Study Group, discusses the CLL2-BIG trial, which explored the combination of obinutuzumab (Gazyva) and ibrutinib (Imbruvica) for induction and maintenance treatment of physically fit and unfit patients with chronic lymphocytic leukemia (CLL). Patients with high tumor burden were given bendamustine as debulking.

Dr. Dadu on Immunotherapy in Thyroid Cancer

January 14th 2017

Ramona Dadu, MD, assistant professor, Department of Endocrine Neoplasia and Hormonal Disorders, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, discusses the use of immunotherapy to treat patients with thyroid cancer.

Dr. Usmani on Importance of CASTOR/POLLUX Trials in Myeloma

January 14th 2017

Saad Z. Usmani, MD, Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute/Carolinas HealthCare System, discusses the importance of the CASTOR and POLLUX trials for the treatment of patients with multiple myeloma.

Dr. Pietrantonio on Survival Rates in Colorectal Cancer

January 14th 2017

Filippo Pietrantonio, MD, Department of Medical Oncology, Medical Oncology Unit, Milan Fondazione IRCCS Istituto Nazionale dei Tumori, discusses survival rates in patients with colorectal cancer.

Dr. Hamieh on Characterization of Poor-Risk Metastatic Kidney Cancer

January 14th 2017

Lana Hamieh, MD, research fellow in Medicine at Brigham and Women’s Hospital, discusses characterization of patients with poor-risk metastatic renal cell carcinoma.

Dr. Yao on Transplants Beyond Milan Criteria for Liver Cancer

January 14th 2017

Francis Yao, MD, gastroenterologist and medical director of the Liver Transplant Program at the University of California San Francisco Medical Center, discusses liver transplants beyond Milan criteria for patients with liver cancer.

Dr. Buffington Discusses Prostate Cancer Screening

January 13th 2017

Philip J. Buffington, MD, chief medical officer, The Urology Group, discusses effective prostate cancer screening methods and when to use active surveillance.

Dr. Ioannou on Treatment Options in Hepatocellular Carcinoma

January 13th 2017

George N. Ioannou, MD, associate professor, VA Puget Sound Health Care System, University of Washington School of Medicine, discusses the best treatment options for patients with hepatocellular carcinoma.

Dr. Kelly on Racial Disparities in Multiple Myeloma

January 13th 2017

Kevin R. Kelly, MD, PhD, associate professor of Medicine, Keck School of Medicine, discusses a study examining racial disparities in patients with multiple myeloma.

Dr. Yardley on tNACity Trial for Triple-Negative Breast Cancer

January 12th 2017

Denise Yardley, MD, senior investigator at the Sarah Cannon Research Institute, discusses the tNACity trial for patients with triple-negative breast cancer.

Lori Sakoda on Genetic Risk Variants for COPD and Lung Cancer

January 12th 2017

Lori C. Sakoda, PhD, research scientist at Kaiser Permanente Division of Research and affiliate investigator of the Division of Public Health Sciences at the Fred Hutchinson Cancer Research Center, discusses her study examining the pleiotropic associations of genetic risk variants for chronic obstructive pulmonary disease (COPD) with lung cancer risk.

Dr. Bekaii Saab on Immunotherapeutic Options in CRC Beyond PD-1/PD-L1

January 12th 2017

Tanios Bekaii-Saab, MD, professor of Medicine, Mayo Clinic, discusses immunotherapeutic options being explored in the treatment landscape of colorectal cancer (CRC) beyond PD-1/PD-L1 agents.